How to Schema

    How to Apply for the Bio Medica Laboratories IPO: Step-by-Step Investment Guide

    Summary:
     

    Bio Medica Laboratories Ltd is a pharmaceutical manufacturing company engaged in producing injectable formulations for human and veterinary healthcare applications. The Bio Medica Laboratories IPO will open for subscription on May 21, 2026, and close on May 25, 2026. The IPO consists of 37,72,000 shares with a price band of ₹132 to ₹139 per share and is proposed to be listed on the SME platform of NSE. The company plans to utilise the issue proceeds for loan repayment, setting up a new manufacturing facility at the existing premises, and general corporate purposes. Investors can apply for the IPO through the ASBA process using net banking or UPI-supported trading platforms before the issue closing date.

    Bio Medica Laboratories Ltd is engaged in the manufacturing of pharmaceutical parenteral formulations, with a focus on injectable medicines used in human and veterinary healthcare. The company manufactures liquid injections and dry powder injections in single-dose and multi-dose formats. Its product portfolio includes generic medicines, branded formulations, and over-the-counter (OTC) products. Operating through a business-to-business (B2B) contract manufacturing model, the company develops formulations according to client-specific requirements and packaging specifications. The company also holds Good Manufacturing Practices (GMP) certification issued by the Food & Drugs Administration, Madhya Pradesh. The company operates two manufacturing facilities in Indore, Madhya Pradesh, and supplies products for pharmaceutical companies under contractual arrangements. Its operations are linked to the pharmaceutical manufacturing segment, particularly injectable formulations used across different healthcare applications.

    Investors planning to apply for the Bio Medica Laboratories Ltd IPO can do so through the ASBA (Application Supported by Blocked Amount) process available via net banking or through UPI-enabled trading applications. Applicants are required to log in to their trading or banking platform, select the IPO section, choose Bio Medica Laboratories Ltd IPO, enter the bid quantity and price within the stated price band, and approve the UPI mandate or ASBA request before the issue closing date.

    For more details, visit the Bio Medica Laboratories IPO page.

    Bio Medica Laboratories IPO Details and Objectives

    Details

    Information

    IPO Date

    May 21, 2026 to May 25, 2026

    Issue Size

    37,72,000 shares (agg. up to ₹52.43 Cr)

    Price Band

    ₹132 to ₹139 per share

    Lot Size

    1,000 shares

    Listing At

    SME, NSE 

    Market Maker

    Prabhat Financial Services Ltd. 

    Purpose of the IPO

    • Repayment of loan

    • Enhancement of the company’s existing production capabilities by setting up of new manufacturing facility at the existing premises

    • General corporate purposes 

    Timeline of Bio Medica Laboratories IPO

    Event

    Date

    IPO Open Date

    Thu, May 21, 2026

    IPO Close Date

    Mon, May 25, 2026

    Tentative Allotment

    Tue, May 26, 2026

    Initiation of Refunds

    Wed, May 27, 2026

    Credit of Shares to Demat

    Wed, May 27, 2026

    Tentative Listing Date

    Fri, May 29, 2026

    Cut-off time for UPI mandate confirmation

    5 PM on Mon, May 25, 2026  

    Pricing & Lot Size of Bio Medica Laboratories IPO

    Price Band for the IPO

    • ₹132 to ₹139 per share

    Minimum Lot Size and Application Details

    Application

    Lots

    Shares

    Amount

    Individual investors (Retail) (Min)

    2

    2,000

    ₹2,78,000

    Individual investors (Retail) (Max)

    2

    2,000

    ₹2,78,000

    S-HNI (Min)

    3

    3,000

    ₹4,17,000

    S-HNI (Max)

    7

    7,000

    ₹9,73,000

    B-HNI (Min)

    8

    8,000

    ₹11,12,000

    Bio Medica Laboratories IPO Application Process

    The Bio Medica Laboratories IPO application process can be completed online through your trading platform. Below is a step-by-step guide to applying for the IPO:

    Step 1: Login to Your Trading Platform

    Access your trading account using the trading platform.

    Step 2: Navigate to the IPO Section

    Go to the IPO section to view active IPO listings.

    Step 3: Select the Open IPO and Click Apply

    Locate Bio Medica Laboratories IPO in the list of available IPOs and click the ‘Apply’ button.

    Step 4: Enter the Quantity of Shares You Wish to Apply For

    Specify the number of shares (lot size: 1000 shares) within the price band of ₹132 to ₹139 per share.

    Step 5: Provide Your UPI ID

    Enter your UPI ID for payment authorisation and ensure sufficient funds in your bank account.

    Step 6: Confirm the Application

    Review your application details and confirm the UPI mandate before 5 PM on the last application day.

    Step 7: Complete the Process and Wait for IPO Allotment Status

    Submit the application and monitor the allotment status to check if shares have been allocated to you.

    Shares Offered in Bio Medica Laboratories IPO

    The allocation of shares in the Bio Medica Laboratories IPO is structured across investor categories in line with applicable regulatory requirements. The issue provides defined reservations for qualified institutional buyers, non-institutional investors, and retail individual investors, with each category allotted a specified proportion of the net issue. This allocation framework outlines how the shares offered are distributed among different classes of investors.

    Investor Category

    Shares Offered

    % of Net Issue

    % of Total Issue

    QIB Shares Offered

    36,000

    1.00%

    0.95%

    NII (HNI) Shares Offered

    17,55,000

    48.98%

    46.53%

      − bNII > ₹10L

    11,70,000

    -

    31.02%

      − sNII < ₹10L

    5,85,000

    -

    15.51%

    Retail Shares Offered

    17,92,000

    50.01%

    47.51%

    Firm Reservations

    Market Maker Shares Offered

    1,89,000

    -

    5.01%

    Total Shares Offered

    37,72,000

    100.00%

    100.00%

    This reservation structure reflects the categorisation and allocation approach disclosed for the issue, indicating the proportion of shares available to each investor segment.

    Financial Health and Performance

    Key Financial Metrics

    • Total Assets: Grew from ₹17.57 crore in FY23 to ₹39.12 crore as of March 2025.

    • Total Income: Recorded at ₹38.33 crore in March 2025, as compared to ₹16.25 crore in FY23.

    • Profit After Tax (PAT): Reported at ₹9.79 crore in March 2025, and ₹0.33 crore in FY23.

    • Net Worth: Recorded at ₹14.73 crore in March 2025 compared to ₹2.44 crore in FY23.

    • Reserves & Surplus: Stood at ₹5.55 crore in March 2025, as compared to ₹2.34 crore in FY23.

    • Total Borrowings: Stood at ₹15.01 crore in March 2025, as compared to ₹9.61 crore in FY23.

    • EBITDA: Stood at ₹15.21 crore in March 2025 in comparison to ₹1.70 crore in FY23.

    Recent Performance and Growth Prospects

    • The company reported growth in its asset base during the reported financial period, reflecting an expansion in operational scale and business activities.

    • Income levels showed an upward trend over the period under review, indicating increased business operations and higher revenue generation from core activities.

    • Profitability improved during the reported period, supported by growth in business performance and operational execution.

    • The company’s net worth strengthened over time, reflecting changes in retained earnings and overall financial position.

    • Reserves and surplus recorded growth during the period, indicating an increase in accumulated earnings within the business.

    • Borrowings also increased during the reported financial years, reflecting the company’s financing requirements for operational and business-related activities.

    • Operating performance, as reflected through EBITDA, showed improvement over the review period, indicating changes in earnings generated from core business operations before finance costs, taxes, depreciation, and amortisation.

    • The company’s financial performance reflects expansion in operations alongside developments in profitability and operational capacity during the stated period.

    Investment Risks and Opportunities

    Potential Risks of Investing in the IPO

    • The company operates through a contract manufacturing business model, which may result in dependence on client-specific orders, agreements, and continuation of business relationships with pharmaceutical companies.

    • The pharmaceutical manufacturing industry is subject to regulatory approvals, quality standards, and compliance requirements. Any changes in regulations, certifications, or operational compliance may affect business operations and manufacturing activities.

    Opportunities and Growth Potential

    • The proposed utilisation of IPO proceeds towards setting up a new manufacturing facility may support expansion in production capabilities and operational capacity over time.

    • The company operates in the pharmaceutical injectable segment and manufactures products catering to both human and veterinary healthcare requirements, which provides exposure to multiple healthcare-related applications and business segments.

    Key Performance Indicator (KPI)

    KPI

    Nov 30, 2025

    Mar 31, 2025

    ROE

    54.41%

    99.59%

    ROCE

    23.22%

    48.20%

    Debt/Equity

    2.23

    1.02

    RoNW

    54.41%

    99.59%

    PAT Margin

    30.35%

    25.64%

    EBITDA Margin

    47.11%

    39.83%

    Price to Book Value

    -

    8.66

    Bio Medica Laboratories IPO Registrar & Lead Managers

    Registrar

    Lead Manager(s)

    Skyline Financial Services Pvt. Ltd.

    Narnolia Financial Services Ltd.

    Company Address of Bio Medica Laboratories Ltd

    Plot No. 11B-11C,

    Sector-E, Sanwer Road

    Industrial Area, Industrial Estate (Indore),

    Indore, Madhya Pradesh, 452015

    Phone: +91 7314102751

    Email: companysecretary@biomedica.co.in

    Website: https://biomedica.co.in/

    Interested in more opportunities? Check out our Upcoming IPO section for new listings and don’t forget to check your Bio Medica Laboratories IPO allotment status.

    Frequently Asked Questions

    Published Date : 21 May 2026

    Disclaimer :

    Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.


    The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes. The securities are quoted as an example and not as a recommendation. Past performance is not necessarily a guide to future performance.

    The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.

    Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.

    BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.



    Content Partner - Dalal Street Investment Journal Wealth Advisory Private Limited



    This article is for educational purposes only and should not be considered investment advice. Market investments are subject to risks. DSIJ Wealth Advisory Private Limited is a SEBI-registered Research Analyst (Reg. No: INH000006396) and Investment Adviser (Reg. No: INA000001142). Please consult your financial adviser before investing. 

    For more disclaimer, check here : https://www.bajajbroking.in/disclaimer

    Read More Blogs

    Our Secure Trading Platforms

    Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

    QR code to download Bajaj Broking App

    9 lakh+ Users

    icon-with-text

    4.9 App Rating

    icon-with-text

    4 Languages

    icon-with-text

    ₹7,300 Cr+ MTF Book

    icon-with-text
    banner-icon

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |